Giles Major
Overview
Explore the profile of Giles Major including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Major G, Dogra S, Sprenger N
Nestle Nutr Inst Workshop Ser
. 2024 Nov;
100:139-149.
PMID: 39586287
The community of microorganisms colonizing the gut changes during the first postnatal years of life. This ecosystem, henceforth described as the microbiome, modulates infant physiology and health, but uncertainty remains...
2.
Yule A, Ng C, Recto A, Lockwood F, Dellschaft N, Hoad C, et al.
J Cyst Fibros
. 2024 Sep;
23(5):984-990.
PMID: 39242338
Background: Gastrointestinal (GI) symptoms in cystic fibrosis (CF) are common and disruptive. The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the GI tract is not fully understood....
3.
Ng C, Dellschaft N, Hoad C, Marciani L, Spiller R, Crooks C, et al.
NIHR Open Res
. 2024 Aug;
3:65.
PMID: 39139270
Background: People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung function but...
4.
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Marsh R, Santos C, Yule A, Dellschaft N, Hoad C, Ng C, et al.
J Cyst Fibros
. 2024 May;
23(5):967-976.
PMID: 38749891
Background: There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study,...
5.
Marsh R, Santos C, Hanson L, Ng C, Major G, Smyth A, et al.
Microbiol Spectr
. 2023 Aug;
:e0117523.
PMID: 37607068
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF. However, there is...
6.
Lionetti P, Wine E, Ran Ressler R, Minor G, Major G, Zemrani B, et al.
Expert Rev Gastroenterol Hepatol
. 2023 Jun;
17(7):665-675.
PMID: 37278084
Introduction: Children who require enteral nutrition often report gastrointestinal symptoms. There is a growing interest in nutrition formulas that meet nutritional requirements and also maintain gut ecology and function. Fiber-containing...
7.
Jalanka J, Gunn D, Singh G, Krishnasamy S, Lingaya M, Crispie F, et al.
Gut
. 2022 Sep;
72(3):451-459.
PMID: 36171082
Objectives: Persistent bowel dysfunction following gastroenteritis (postinfectious (PI)-BD) is well recognised, but the associated changes in microbiota remain unclear. Our aim was to define these changes after gastroenteritis caused by...
8.
Poon D, Law G, Major G, Andreyev H
Sci Rep
. 2022 Feb;
12(1):1949.
PMID: 35121775
Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions-bile acid diarrhoea (BAD), carbohydrate malabsorption (CM), microscopic colitis...
9.
Impact of home parenteral nutrition on family members: A national multi-centre cross-sectional study
French C, Lal S, Jones D, Sowerbutts A, Brundrett D, Burch N, et al.
Clin Nutr
. 2022 Jan;
41(2):500-507.
PMID: 35007818
Background & Aims: Home parenteral nutrition (HPN) is a necessary treatment for patients with chronic, type 3, intestinal failure (IF). HPN often requires lifestyle adaptations, which are likely to affect...
10.
Dellschaft N, Ng C, Hoad C, Marciani L, Spiller R, Stewart I, et al.
J Cyst Fibros
. 2021 Dec;
21(3):502-505.
PMID: 34922853
People with cystic fibrosis (CF) experience digestive symptoms but the mechanisms are incompletely understood. Here we explore causes and consequences of slower gastrointestinal transit using magnetic resonance imaging (MRI). Twelve...